BARKAN PHARMA ISRAEL LTD
Barkan Pharma Israel LTD
Barkan Pharma Israel is a pharmaceutical company dedicated to the development of drugs and the holding company of Barkan Farma (Moldova). Both companies work in cooperation for the pipeline market development at a worldwide level.
The business plan contemplates that Barkan Pharma Israel will acquire the rights for the Radioprotection Project from Aminolab Technologies and take the lead to fully develop this project. For this purpose and for additional developments Barkan Pharma Israel intends to raise an investment of $ 5 million within 12 months.
Mr. Barkan's holdings comprise several private companies within the biotechnology and pharmaceutical industries with solid and wide professional experience as well as new and effective drug developments addressing large markets with unmet needs.
The companies are synergetic in their activities providing analytical laboratories and contract manufacturing services and the infrastructure necessary to support the research and development activities of the drug research and development companies.
The synergism amid the companies allows an efficient organization structure maximizing the management and financial services and maintaining a low burn rate.
One of the leading analytical laboratories in Israel, Aminolab provides its customers professional expertise, supported by modern laboratories, for a wide variety of analytical areas and all under one roof.
Aminolab, centrally located in the Weizmann Science Park in Ness Ziona, is housed in modern state-of-the-art facilities and staffed by highly qualified and experienced professionals.
Aminolab was founded in 1988 by Mr. Rafi Barkan as a small laboratory, specializing in amino acid analysis, and has since gained market recognition for its quality services by hundreds of customers in Israel and abroad. Mr. Barkan has been the Chairman of the company since its establishment.
Aminolab Laboratories follow either ISO/IEC 17025, GLP (Good Laboratory Practice) or GMP (Good Manufacturing Practice) guidelines. The Quality Assurance & Regulatory Affairs program conforms to the USA FDA, EPA and global QA requirements.
Aminolab’s specialized laboratories are serving the following industries and disciplines:
Medical Devices: sterility tests, shelf life studies and packaging integrity
Cosmetics: submission of application requests, certification for imported cosmetics
Environmental: air, solid, sludge and wastewater
Food composition: safety and additives, water analysis and vitamins
Pesticide Residues: in fruits, vegetables, soil and water
BioPharmaceuticals: drugs, natural products, amino acid analysis
The annual revenue of the company is approximately $ 9 million with a net profit of $1 million (after taxes). The annual growth rate is projected to be at least 15% – 20% for the next 5 years.
The laboratories are recognized as the number one analytical services provider for its Quality level. Aminolab is a solid company with a strong reputation and a very good growth potential for the next years.
Aminolab Technologies 2000 Ltd.
Aminolab Technologies 2000 Ltd. was established in 1999 with the mission to identify investment opportunities in early stage biotechnology, medical and pharmaceutical start-ups.
Aminolab Technologies has extensive experience in supporting pharmaceutical and drug development companies. The portfolio companies benefit from management, marketing and business mentoring and guidance. The management team invests financially in the portfolio companies. In addition, analytical and research tools are offered to them. The most successful companies established by Aminolab Technologies 2000 Ltd. are Meditor Pharmaceuticals Ltd., Barkan Farma SRL. And most recently the promising Radioprotection Project development.
Radioprotection Project
Aminolab Technologies Ltd is planning to take a novel approach to develop pharmacological compounds that will strengthen the body’s internal systems providing a safe, effective and affordable radiation-protection drug. Three different molecule categories that contain strong radio protective record are the source and basis to a new R&D program, aiming to develop:
-
Medical Countermeasures against possible war or terrorist attack involving radioactive materials in a form of a pre treatment in case of a nuclear threat. Preferably in a tablet form or for self-injection.
-
The same Medical Countermeasures in a form of post irradiation (e.g. up one hour after the nuclear attack). Preferably in a tablet form or for self-injection or to be treated in Hospitals.
-
A preventive treatment to minimize normal tissue damage during cancer radiotherapy and any other radiation risks.
The company intends to continue the development and manufacturing of the molecule. For this purpose is planning to raise EUR 5 million in equity. The project has huge potential with an estimated drug market of over $ 100 million annually.
Aminolab Ltd.
Holdings - Refael Barkan
Aminolab Ltd.
32.5%
Barkan Pharma
Israel Ltd
100%
Barkan Farma SRL
(Moldova)
99%
Aminolab
Technologies 2000
Ltd.
86%
Meditor
Pharmaceuticals
Ltd.
(25% holding by Aminolab Technologies)
Radioprotection Project
(100% holding by Aminolab Technologies)
Meditor Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to the development and commercialization of proprietary products for the therapeutic management of Migraine, acute and chronic hypotension disorders. Meditor holds several worldwide patents that strongly support its intellectual property base.
Meditor’s clinical development program is focused on the lead compound MTR104, a synthetic small molecule. The FDA granted Meditor an IND Number 66,505 authorizing the beginning of two Phase II clinical trials for hypotension related disorders.
MTR106 tablets for Migraine - A preliminary open label study on 100 patients, carried out during 2001/2, demonstrated the efficacy of MTR106 in alleviating migraine attacks. Meditor completed a Phase II randomized double blind, placebo-controlled dose-escalating study in 40 women in 2007. The study was conducted under cGCP and assessed the pharmacokinetics of MTR106 tablets for the treatment of acute migraine attacks. In light of the positive results from the Clinical Trials, Migraine is the leading indication of the R&D program.
MTR105 IV for Cardiac Surgery-Related Hypotension - Accumulated clinical experience proved MTR105 to be safe and highly effective in stabilizing blood pressure in patients with cardiac surgery-related hypotension. A new clinical study is currently undergoing in the USA.
MTR-108 for the treatment of Menorrhagia and Excessive Postpartum Bleeding: exclusive vaginal tablets indicated for menorrhagia and excessive postpartum bleeding. Prescription drug. In clinical development.
Recently a term sheet was signed with Arkin Holdings, for the development of a dermal ointment application of the company's molecule. Arkin Holdings is owned by Israeli businessman Mr. Mori Arkin, former CEO & owner of the pharmaceutical company Agis (Perrigo). In the framework of the agreement Arkin Holdings will investment the funds for drug development. Meditor will receive milestone fees in accordance to the development progress, which can reach $ 3.5 million in a period of up to three years. Once the development is completed and the drug approved and commercialized Meditor will be entitled to royalties from sales for several millions annually.
Meditor is reorganizing its structure and focusing its business plan on two main developments and for this purpose the company is initially raising an investment of $ 2 million.
Meditor's objective is to quickly focus on the development of its lead drug MTR-106 for the treatment of Migraine and conducting a Phase II clinical trial in the US under FDA guidelines. A successful completion of this first milestone will give the investors and attractive exit point at a high valuation of approximately $ 100 million as estimated by experts. This milestone is feasible in a period of 18 months once initial investment to conduct Phase II trials is available.
In addition, Meditor strategy considers merging the drug pipeline with Barkan Farma's and continue together the clinical development of Raviset, indicated for menorrhagia and excessive postpartum bleeding.
Barkan Farma SRL
Barkan-Farma S.R.L. is a privately held pharmaceutical company established in 2007 in Moldova.
Barkan-Farma S.R.L. was established as a unique ethical drug company. The Company's mission is to serve the unmet needs of the chosen Eastern European and Central Asia pharmaceutical markets while capitalizing on their untapped market opportunity and outstanding market growth.
Barkan-Farma is committed to developing therapeutic advancements for a range of disorders with unmet medical needs. The Company has received a License from Meditor Pharmaceuticals to develop and commercialize its products in Eastern Europe. Initially the company is focused on the migraine treatment, surgery related hypotension, menorrhagia and nasal congestion therapies. This products pipeline alone addresses more than $ 25 million opportunity in the Eastern European and Central Asia regions markets.
Barkan Farma has already been registered Ravimig for the treatment of Migraine and successfully commercializes in Moldova. This has been an excellent pilot entry point to the market in order to move forward to additional Easter Europe markets.